WCLC 2021 | KRAS-mutant NSCLC: CodeBreak 100 trial of sotorasib

Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the results of the Phase II CodeBreak 100 trial (NCT03600883) of sotorasib in advanced non-small cell lung cancer, highlighting the study as one of the top updates presented at WCLC 2021. Sotorasib is a a first-in-class irreversible inhibitor of KRAS-G12C and was used as a single agent to treat patients with advanced or metastatic KRAS p.G12C-mutant NSCLC. The trial gave promising progression-free survival and overall response rate data. Prof. Peled shares his thoughts on why sotorasib may be a breakthrough in lung cancer therapy. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.